Rehabilitation After a Hip Fracture: the Effects of Dietary Protein and Exercise on Bone and Muscle Health and Quality of Life

Summary

Hip fractures often lead to functional limitations, loss of independence, weight loss and decreased well-being. Only half of the patients regain their functional level and 24% die within the following year. Financial consequences are significant due to costly surgery and long-term care. Hip fracture incidence is expected to increase sharply due to the ageing population, reducing accessibility to and quality of rehabilitation care. Therefore, optimizing treatment is essential.

Previous protein and exercise studies showed improved muscle and bone health in healthy or frail community-dwelling older adults, but effects in older hip fracture patients are not known. Better rehabilitation may improve bone and muscle health, nutritional status, quality of life, lower costs and lower burden for healthcare.

The overall objective is to investigate the effectiveness, costs and cost-effectiveness of a protein-enriched diet and resistance exercise for 3 months compared to usual care on bone and muscle health, and quality of life in older adults recovering from an acute hip fracture.

Conditions

• Hip Fractures

Interventions

OTHER

Protein-enriched diet

A protein intake of 1.5 g/kg bodyweight/day. This will be obtained by consuming protein-rich and protein-enriched foods.

OTHER

Progressive resistance exercise

The intervention group will perform resistance training during three non-consecutive days with a minimum of 48 hours between the sessions. Subjects will continue the resistance training after discharge for 2 times a week, also with a minimum of 48 hours between sessions until the study period of 3 months is completed. All sessions will be supervised by physiotherapists.

Sponsors & Collaborators

• Rijnstate Hospital

  collaborator OTHER

• Gelderse Vallei Hospital

  collaborator OTHER

• HAN University of Applied Sciences

  collaborator OTHER

• Liemerije Revalidatiezorg

  collaborator UNKNOWN

• Opella Revalidatiezorg

  collaborator UNKNOWN

• Pleyade Revalidatiezorg

  collaborator UNKNOWN

• Attent Zorg en Behandeling

  collaborator UNKNOWN

• Alliantie Voeding in de Zorg

  collaborator UNKNOWN

• Osteoporosis Association

  collaborator UNKNOWN

• Wageningen University

  lead OTHER

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Model

PARALLEL

Eligibility

Min Age

65 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2024-09-01

Primary Completion

2026-08-31

Completion

2026-08-31

Countries

• Netherlands

Study Locations